Scientists have reversed Alzheimer’s disease in mice, potentially showing a pathway to treat the illness among humans, according to a Dec. 22 peer-reviewed study published in the Cell Reports Medicine journal. Alzheimer’s is traditionally considered irreversible. In the study, researchers treated two groups of mice with P7C3-A20, a pharmacologic agent. One group carried human mutations related to amyloid processing, while the other carried a tau protein mutation. Both amyloid and tau pathologies are two major early events of Alzheimer’s. Researchers say that as mice develop brain pathologies resembling Alzheimer’s, they are ideal subjects to test how P7C3-A20 affects Alzheimer’s in humans. Among the amyloid mice, treatment with P7C3-A20 was found to have resulted in restoring the proper balance of Nicotinamide adenine dinucleotide (NAD+), which is a cellular energy molecule and a major driver of Alzheimer’s disease. As people age, NAD+ levels decline in their bodies, including the brain. Without proper NAD+ balance, the cells are unable to execute critical processes necessary for proper functioning. The treatment was found to have reversed blood-brain barrier deterioration, DNA damage, oxidative stress, and neuroinflammation, researchers wrote. The blood-brain barrier maintains nutrient and hormone levels in the brain while protecting the organ from toxins and pathogens. The treatment enhanced […]